Connecting COVID-19 antibody responses to disease protection, one data set at a time
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Reports that most if not all COVID-19 survivors have antiviral antibodies are beginning to set benchmarks for immunity, but understanding how much protection different levels and types of antibodies provide will be critical for determining how well COVID-19 vaccines work.
The idea that exposure to a virus triggers production of antibodies that protect individuals